The company’s stem cell technology-based bioassay platform, Human Clinical Trials in a Test TubeTM, is designed to provide early and accurate predictions of the potential toxicity of otherwise promising new drug candidates, long before they are actually tested on animals or humans. Such bioassay systems more closely approximate human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development. Advanced awareness of potential toxicity would be of tremendous value to drug developers, representing a huge potential savings and allowing them to focus and optimize their development expenditures.
VistaGen’s CardioSafe 3D™ is a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates on the heart. The company plans to use CardioSafe 3D™ to build a pipeline of small molecule drug rescue variants of once-promising drug candidates that have been “put on the shelf” by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite positive efficacy data signaling their potential therapeutic and commercial benefits.
VistaGen is also developing LiverSafe 3D™, a predictive liver toxicity and drug metabolism bioassay system for drug rescue applications.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
